依托泊苷联合用药作为晚期霍奇金病的一线化疗方案。癌症与白血病B组研究。

Etoposide in combination as first-line chemotherapy for advanced Hodgkin disease. A Cancer and Leukemia Group B study.

作者信息

Kirshner J J, Anderson J R, Parker B, Barcos M, Cooper M R, Burns L J, Peterson B A, Gottlieb A J

机构信息

S.U.N.Y. Health Science Center.

出版信息

Cancer. 1993 Mar 1;71(5):1852-6. doi: 10.1002/1097-0142(19930301)71:5<1852::aid-cncr2820710523>3.0.co;2-t.

DOI:10.1002/1097-0142(19930301)71:5<1852::aid-cncr2820710523>3.0.co;2-t

PMID:8448749

Abstract

BACKGROUND

In a pilot study, Cancer and Leukemia Group B (CALGB) incorporated etoposide into primary combination therapy for advanced Hodgkin disease.

METHODS

Thirty-six evaluable patients were treated with two or three courses of methotrexate, vincristine, prednisone, leucovorin, etoposide, and cyclophosphamide (MOPLEC), and then treated with five to seven additional courses of a known "curative" regimen: nitrogen mustard, vinblastine, prednisone, and procarbazine (MVPP).

RESULTS

After treatment with MOPLEC, there were 16 complete responders (44%) and 18 partial responders (50%). One patient had progressive disease and one patient was taken off study after an anaphylactic reaction to etoposide. After completing the entire protocol, 32 patients achieved complete remission (CR) (89%) and 3 achieved partial remission (PR) (8%). Five CR patients have relapsed and three additional patients have died in CR without recurrence. At 36 months, the estimated failure-free survival is 61% and overall survival is 72%.

CONCLUSIONS

This combination, which includes etoposide, is active for the primary treatment of advanced Hodgkin disease.

摘要

背景

在一项初步研究中，癌症与白血病B组（CALGB）将依托泊苷纳入晚期霍奇金病的初始联合治疗方案。

方法

36例可评估患者接受了两到三个疗程的甲氨蝶呤、长春新碱、泼尼松、亚叶酸钙、依托泊苷和环磷酰胺（MOPLEC）治疗，然后再接受五到七个疗程的已知“治愈性”方案治疗：氮芥、长春花碱、泼尼松和丙卡巴肼（MVPP）。

结果

接受MOPLEC治疗后，有16例完全缓解者（44%）和18例部分缓解者（50%）。1例患者病情进展，1例患者在对依托泊苷发生过敏反应后退出研究。完成整个方案后，32例患者实现完全缓解（CR）（89%），3例患者实现部分缓解（PR）（8%）。5例CR患者复发，另外3例CR患者无复发死亡。36个月时，估计无失败生存率为61%，总生存率为72%。